Paradigm Biopharmaceuticals Completes Phase 3 Enrollment
Key points
- Phase 3 Enrollment Completed with 538 Participants
- Independent Safety Review Finds No Material Safety Concerns
- Capital Raise of A$21.38 Million Completed
- Top-Line Phase 3 Results Expected in Q1 2027
- Engagement with Potential Partners for Licensing Opportunities
Full summary
Paradigm Biopharmaceuticals Ltd. has completed enrollment in its global pivotal Phase 3 PARA_OA_012 study for Zilosul®, exceeding the target with 538 participants. The study is on track for an interim analysis in September 2026, with top-line results expected in Q1 2027. An independent safety review found no material safety concerns, and the company raised approximately A$21.38 million through a placement and share purchase plan. Additionally, Paradigm presented biomarker findings at the OARSI 2026 World Congress and engaged with potential partners at the BIO International Convention 2026.
Guidance
Top-line Phase 3 results expected in Q1 2027
Outlook
Paradigm is focused on clinical follow-up, data quality, and preparing for the interim analysis and primary endpoint top-line results.
Summary generated by a large language model. Please interpret with care.